Results 161 to 170 of about 164,269 (359)

Chronic high‐fat diet induces multi‐organ dysfunction and metabolic homeostasis disruption in Macaca fascicularis

Animal Models and Experimental Medicine, EarlyView.
An 18‐month HFD successfully established a translational Macaca fascicularis model replicating key metabolic disorders (MASH, diabetes, cardiac hypertrophy). MASH was determined by liver biopsy histology, the presence steatosis, inflammatory infiltration, hepatocytic ballooning, and fibrosis were considered as MASH; diabetes was diagnosed according to ...
Hongyi Chen, Wei Liu, Dan Zhou, Shuhua Liu, Yalun Guan, Zongyu Miao, Lei Cai, Xuejiao Li, Yunfeng Li, Zhongqiang Huang, Yi Jin, Ge Li, Yu Zhang   +12 more
wiley   +1 more source

RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease

Hepatology, EarlyView., 2022
RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease. Abstract Background and Aims Receptor‐interacting protein kinase 3 (RIPK3) mediates NAFLD progression, but its metabolic function is unclear. Here, we aimed to investigate the role of RIPK3 in modulating mitochondria function, coupled with lipid droplet (LD)
Marta B. Afonso, Tawhidul Islam, Julie Magusto, Ricardo Amorim, Véronique Lenoir, Rui F. Simões, José Teixeira, Liana C. Silva, Dominique Wendum, Isabelle Jéru, Corinne Vigouroux, Rui E. Castro, Paulo J. Oliveira, Carina Prip‐Buus, Vlad Ratziu, Jérémie Gautheron, Cecília M. P. Rodrigues   +16 more
wiley   +1 more source

Inhibition of mTOR improves the impairment of acidification in autophagic vesicles caused by hepatic steatosis [PDF]

, 2015
Eisuke Nakadera, Shunhei Yamashina, Kousuke Izumi, Yoshihiro Inami, Toshifumi Sato, Hirofumi Fukushima, Kazuyoshi Kon, Kenichi Ikejima, Takashi Ueno, Sumio Watanabe   +9 more
openalex   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

Hepatology, EarlyView., 2022
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr, Benedikt Kaufmann, Maria Eugenia Inzaugarat, Theresa Maria Holtmann, Lukas Geisler, Jana Hundertmark, Marlene Sophia Kohlhepp, Laela M. Boosheri, Daisy R. Chilin‐Fuentes, Amanda Birmingham, Kathleen M. Fisch, Joel D. Schilling, Sven H. Loosen, Christian Trautwein, Christoph Roderburg, Münevver Demir, Frank Tacke, Hal M. Hoffman, Ariel E. Feldstein, Alexander Wree   +19 more
wiley   +1 more source

Longitudinal Modulation of the Gut Microbiome and Growth Performance by Phytochemicals as Antibiotic Alternatives in Swine Production

Animal Research and One Health, EarlyView.
We conducted a longitudinal trial across nursery, growing, and finishing phases, showing that phytochemical supplementation as a potential antibiotic alternative reduced potential pathogens and promoted beneficial Lactobacillus amylovorus in the nursery phase, and enriched amino acid and carbohydrate metabolism pathways (prediction) during finishing ...
Ziyu Liu, Samantha Howe, Yang Tian, Alisun N. Watson, Jason E. Farrar, Christopher E. Randolph, Jaime Andrés Ángel Isaza, Álvaro José Uribe, Yan Huang, Michael Looper, Jiangchao Zhao, Tsungcheng Tsai   +11 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source

Cytosolic lipid trafficking proteins STARD4 and STARD5 modulate hepatic neutral lipid metabolism: implications for diabetic dyslipidaemia and steatosis [PDF]

, 2015
Dolan, Sharron, Graham, Annette, Soffientini, Ugo   +2 more
core   +1 more source

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source